This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
HealthEquity Stock Gains as Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
HQY surpasses fiscal first-quarter revenue expectations on robust HSA growth. The company also updates its fiscal 2026 guidance.
Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
by Zacks Equity Research
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks.com featured highlights StoneCo, Centene, CVS Health and Pfizer
by Zacks Equity Research
StoneCo, Centene, CVS, and Pfizer stand out as top value picks with strong cash flow amid market uncertainty.
Hyperfine Stock Rises After FDA Clears Next-Gen Swoop MRI System
by Zacks Equity Research
HYPR secures FDA clearance for its next-gen Swoop system, advancing bedside MRI tech and reinforcing its mission to revolutionize accessible neuroimaging.
Top 4 Value Stocks to Buy as Trade Tensions Still Cloud H2 Outlook
by Sumit Singh
STNE, CNC, CVS and PFE stand out as top value picks amid trade tensions and a murky H2 economic outlook.
Vivani Stock Gains After Announcing Spin-Off Plans for Cortigent Unit
by Zacks Equity Research
VANI is set to spin off Cortigent, aiming to sharpen its focus on drug implants and unlock long-term value for both entities.
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes
by Zacks Equity Research
BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.
COO Q2 Earnings Beat, 2025 Sales Outlook Tightened, Stock Down
by Zacks Equity Research
COO's fiscal Q2 earnings and sales beat market expectations on the back of strong growth. Improvement in operating margin bodes well.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Add HealthEquity Stock to Your Portfolio Now
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
VEEV Stock Up as Q1 Earnings & Revenues Beat Estimates, Margin Rise
by Zacks Equity Research
Veeva Systems' fiscal first-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.
Reasons to Retain The Cooper Companies Stock in Your Portfolio Now
by Zacks Equity Research
COO benefits from the strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
5 Valuable Price-to-Book Stocks to Strengthen Your Portfolio
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and PSFE are some such stocks.
Buy 5 High Dividend-Paying Giants to Stay Safe Amid Volatile Markets
by Nalak Das
PM, CVS, ET, GSK and NWG, which offer high dividends and carry Zacks buy ranks, are strong picks for stability amid volatile market conditions of 2025.
CVS or Cigna: Which Diversified Healthcare Stock Should You Own Now?
by Urmimala Biswas
CVS rallies on turnaround momentum and EPS growth, while CI is a defensive play with stable returns and a focused healthcare strategy.
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
by Zacks Equity Research
NeuroPace reports promising one-year results from its NAUTILUS trial, showcasing the RNS System's effectiveness in treating idiopathic generalized epilepsy with sustained seizure reduction.
Reasons to Retain Veeva Systems Stock in Your Portfolio for Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
BioSig Stock Surges Following Share Exchange Deal With Streamex
by Zacks Equity Research
BSGM merges with Streamex to enter the blockchain space, aiming to revolutionize commodity tokenization and expand its footprint in digital asset markets.
CVS or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
PacBio Stock Slips Despite New China Distribution Deal With Haorui
by Zacks Equity Research
PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.